ArticleAvicenna journal of phytomedicine
Comparison the effect of Asvard capsule and omeprazole in treatment and recurrence of non-cardiac chest pain related to gastroesophageal reflux disease in adults: A controlled double blind clinical trial.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Considering the burden of non-cardiac chest pain (NCCP) on emergency departments and the difficulties related to the treatment of the disorder, the present study aims to investigate the effect of Asvard capsule (containing Materials and Methods: This study was carried out for 8 weeks including 6 weeks of therapeutic intervention and 2 weeks of follow-up. The participants were assigned to a control group that received omeprazole capsule 20 mg/day and three intervention groups A) Asvard capsule 1200 mg/day )2 cap 300 mg/BID), B) Asvard capsule 1600 mg/day (2 cap 400 mg/BID), and C) Asvard capsule 2000 mg/day (2 cap 500 mg/BID). The therapeutic efficiency for NCCP was assessed in 4 phases (days 0, 21, 42, and 56) using a standardized questionnaire of frequency scale for the symptoms of gastroesophageal reflux disease (FSSG). Results: The average value of NCCP was reduced after the intervention compared to the study's baseline in all groups (Pv <0.001). However, two weeks after treatment (follow-up), participants recorded higher scores of NCCP in the omeprazole 20 mg group, the average of NCCP for the intervention groups remained constant or increased slightly. Conclusion: Our findings present that although omeprazole 20 mg decreased chest pain score, it has less lasting effect compared to the herbal medicine used in this study. It seems that Asvard can be effective for the treatment of NCCP related to gastroesophageal reflux disease (GERD), however, a long-term study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.